This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

Increased serotonin 1B receptor binding in the brain: a shared mechanism of action of ketamine and electroconvulsive therapy in depression

Increased serotonin 1b receptor binding in the brain - a shared mechanism of action of ketamine and electroconvulsive therapy for depression

Ketamine and electroconvulsive therapy, two rapid-acting treatments for depression, share the effect of increasing serotonin 1B receptor binding in the brain.

Although the mechanisms of action of ketamine and electroconvulsive therapy (ECT) in major depressive disorder (MDD) remain unknown, both share a rapid onset of action and a dose-dependent increase in serotonin; this study investigated the role of the serotonin 1B receptor (5-HT1BR), which inhibits serotonin release, in this shared effect. Previous studies had reported increased 5-HT1BR binding after both ketamine and ECT, but this increase could not be distinguished from placebo. In this study, data from two clinical positron emission tomography (PET) studies using the 5-HT1BR-selective radioligand [11C]AZ10419369 were reanalyzed using SiMBA (Simultaneous Multifactor Bayesian Analysis of PET Data), a hierarchical Bayesian method that leverages similarities in parameters within and across individuals and regions. PET scans were performed before and within one week after completion of a course of ECT for depression (n = 13), or before and 1-3 days after a single infusion of ketamine (n = 19) or placebo (n = 10) for MDD; additional PET data were incorporated into the overall model to improve parameter estimation, and the combined dataset included 222 [11C]AZ10419369 measurements obtained at three separate PET centers. Brain 5-HT1BR binding increased after both ketamine (6.4%, 95% CI: 3.1-9.6%) and ECT (9.3%, 95% CI: 4.3-14.2%), and this increase was greater after active treatment than after placebo. The authors note that further studies are needed to investigate whether 5-HT1BR activation could benefit patients with MDD.

All WCP 2026 summaries